CTIS2023-504816-14-00招募中1 期
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095) - MK-2870-005
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 690
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
入选标准
- •Histologically-confirmed diagnosis of endometrial carcinoma or carcinosarcoma., Radiographically evaluable disease, either measurable or nonmeasurable per RECIST 1.1, as assessed by BICR., Received prior platinum-based chemotherapy and anti- programmed cell death 1 protein (PD-1)/anti- programmed cell death ligand 1 (PD-L1) therapy, either separately or in combination.
排除标准
- •Neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of pure sarcomas., History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing., Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease., Recurrence of endometrial carcinoma or carcinosarcoma more than 180 days after completing platinum-based therapy administered in the curative-intent or adjuvant setting without any additional platinum-based therapy received in the metastatic or recurrent setting., Received more than 3 prior lines of therapy for endometrial carcinoma or carcinosarcoma.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3, Randomized, Active-controlled, Open-label, Multi-Center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with EpoetinEstudio fase III, aleatorizado, controlado con tratamiento activo, abierto y multicéntrico, de la seguridad y eficacia de la inyección de AF37702 para el tratamiento de mantenimiento de la anemia en pacientes en hemodiálisis previamente tratados con eritropoyetina - EMERALD 2Maintenance treatment of anemia in hemodialysis patientsTratamiento de mantenimiento de la anemia en pacientes en hemodiálisisMedDRA version: 9.1Level: LLTClassification code 10002272Term: AnemiaEUCTR2007-004153-28-ESAffymax Inc.750
进行中（未招募）
不适用
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epoetin - EMERALD 2Anemia in Hemodialysis PatientsMedDRA version: 9.1Level: LLTClassification code 10002034Term: AnaemiaEUCTR2007-004153-28-ITAFFYMAX INC.750
进行中（未招募）
不适用
A Phase 3, Randomized, Active-controlled, Open-label, Multi-Center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epoetin - EMERALD 2Maintenance treatment of anemia in hemodialysis patientsMedDRA version: 9.1Level: LLTClassification code 10002272Term: AnemiaEUCTR2007-004153-28-PLAffymax Inc.750
进行中（未招募）
不适用
A Phase 3, Randomized, Active-controlled, Open-label, Multi-Center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epoetin - EMERALD 2Maintenance treatment of anemia in hemodialysis patientsMedDRA version: 9.1Level: LLTClassification code 10002272Term: AnemiaEUCTR2007-004153-28-GBAffymax Inc.750
进行中（未招募）
1 期
A Phase 3, Randomized, Active-controlled, Open-label, Multi-Center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epoetin - EMERALD 2EUCTR2007-004153-28-FRAffymax Inc.750